DUTOGLIPTIN TARTRATE

Dutogliptin is a DPP‑4 inhibitor enhancing incretin activity to improve glycemic control. Side effects include nasopharyngitis, headache, and rare pancreatitis.

SKU: 01b905e8ebdf Category: Tag:

Product Description


Mechanism of Action

Dutogliptin is a selective DPP‑4 inhibitor that prevents degradation of incretin hormones (GLP‑1, GIP). This prolongs insulinotropic signalling, enhances glucose‑dependent insulin release and suppresses inappropriate glucagon secretion.

Benefits and Advantages

Used in incretin‑pathway modulation studies, DPP‑4 inhibition assays, glucose‑regulation modelling, and combination‑therapy research with GLP‑1 agonists.

Side Effects and Risks

Risks include nasopharyngitis, headache, joint pain and rare pancreatitis. Handle with enzyme‑inhibitor precautions.

Datasheet


Molecular Formula

C14H26BN3O9

Molecular Weight

391.18 g/mol

CAS Number

890402-81-0

Storage Condition

Store in a cool, dry place. Keep container tightly closed. Protect from moisture and light.

Solubility

Solubility depends on solvent and conditions (e.g., pH). Please contact us for solvent-specific guidance.

Purity

Purity information is available upon request (COA).

Synonym

Dutogliptin tartrate; 890402-81-0; Dutogliptin tartrate [USAN]; UNII-79QH89EV9M; 79QH89EV9M

IUPAC/Chemical Name

(2R,3R)-2,3-dihydroxybutanedioic acid;[(2R)-1-[2-[[(3R)-pyrrolidin-3-yl]amino]acetyl]pyrrolidin-2-yl]boronic acid

InChl Key

SVWHNLVZPGXBNS-MHDNXTQBSA-N

InChl Code

InChI=1S/C10H20BN3O3.C4H6O6/c15-10(7-13-8-3-4-12-6-8)14-5-1-2-9(14)11(16)17;5-1(3(7)8)2(6)4(9)10/h8-9,12-13,16-17H,1-7H2;1-2,5-6H,(H,7,8)(H,9,10)/t8-,9+;1-,2-/m11/s1

References

https://pubchem.ncbi.nlm.nih.gov/compound/15949100;

3D Conformer.

(Click, turn or enlarge)

Download our GMP API Product List.

MedicaPharma is an EU-based supplier of GMP-certified APIs that serves leading healthcare institutions and research organizations.
Click here to download our full API product list.

Download